Herpes simplex virus type 2 (HSV-2) glycoprotein B (gB-2) gene segments were expressed as recombinant proteins in Escherichia coli. gB-2 recombinant proteins were reacted with human serum immunoglobulin G (IgG) antibodies in Western immunoblot assays. Initially, samples were tested for the presence of HSV-1-specific antibodies and HSV-2-specific antibodies by using HSV-infected cell lysates as antigen targets in Western blot assays. Serum samples that contained HSV-2-specific IgG (n ‫؍‬ 58), HSV-1-specific IgG (n ‫؍‬ 33), or no detectable HSV antibodies (n ‫؍‬ 31) were tested for reactivities with the gB-2 recombinant proteins. In 58 of 58 samples that contained HSV-2-specific IgG, antibodies were present that reacted strongly with a gB-2 amino-proximal segment between amino acids (aa) 18 and 75. Three of 33 serum samples that contained HSV-1-and not HSV-2-specific IgG (as defined by the HSV lysate Western blot assay) reacted with this segment. Both HSV-2 antibodies and HSV-1 antibodies reacted strongly with a carboxy-terminal gB-2 segment between aa 819 and 904; a second minor cross-reactive region was mapped to a gB-2 segment between aa 564 and 626. The gB-2 segment from aa 18 to 75 may constitute a useful reagent for the virus type-specific serodiagnosis of HSV-2 infections. Further studies will be required to determine the relative sensitivities and specificities of the assay for gB-2 aa 18 to 75, HSV gG assays, and HSV lysate Western blot assays for detecting virus type-specific antibody responses in acute and chronic HSV-2 infections.
The herpes simplex virus (HSV) glycoprotein B (gB) is a transmembrane envelope glycoprotein that contributes to the penetration of virions into host cells (6, 15, 16, 22, 48, 53, 54) . gB induces fusion of the virion envelope with the cellular cytoplasmic membrane, an essential function for virus entry (6, 15) . Immunization of humans and animals with purified gB induces virus-neutralizing antibody responses, and recombinant gB proteins are being investigated as HSV vaccines (9-12, 17, 19, 24, 43, 44, 45, 55) .
The HSV type 2 (HSV-2) gB (gB-2) polypeptide contains 904 amino acids (aa) (13, 56) . The amino-terminal segment (22 aa ) is a signal peptide that is cleaved from the mature protein during processing. aa 745 to 798 constitute a hydrophobic transmembrane anchor domain. The segment carboxy proximal to the anchor domain (aa 799 to 904) is cytoplasmic and appears to mediate membrane fusion (14-16, 22, 25, 50) . The amino-proximal segment (aa 23 to 744) is extracellular and contains epitopes that are recognized by virus-neutralizing antibodies (27, 28, 46) .
HSV-2 and HSV-1 are closely related viruses. Most of their homologous proteins are highly conserved (20, 42) and elicit cross-reactive antibody responses (2, 8, 41, 57) . HSV-2 and HSV-1 infections elicit strong immunoglobulin G (IgG) antibody responses to the HSV-2 gB-2 and to the HSV-1 gB-1, respectively (4, 20, 42) . gB antibodies are detectable early in acute infections, attain high titers, and persist for many years (2, 20, 23) . gB-2 polyclonal antibody responses include antibodies that cross-react with gB-1, and gB-1 responses include antibodies that cross-react with gB-2 (2, 8, 41, 57) . The antigenic relatedness of gB-2 and gB-1 is consistent with the marked overall conservation of their amino acid sequences (86% at the amino acid level) (13) .
In contrast to most HSV-2 and HSV-1 homologous proteins, HSV-2 gG-2 and HSV-1 gG-1 have highly dissimilar amino acid sequences. Human gG-2 and gG-1 antibody responses induced by HSV-2 and HSV-1 infections, respectively, appear to be virus type specific (8, 40) . Detection of reactivities to gG-1 and gG-2, either present as native viral proteins or produced as recombinant antigens, forms the basis for current HSV type-specific antibody assays (1, 4, 5, 47) .
Although cross-reactive antibodies are represented in the human IgG responses to gB-2 and gB-1, respectively, virus type-specific gB antibodies may also be induced by HSV infections. Some murine monoclonal antibodies generated against gB-1 cross-react with gB-2, but others are virus type specific. Linear (continuous) epitopes that react with type-specific, virus-neutralizing murine monoclonal antibodies have been localized to the extracellular amino-terminal segment of gB-1 (21, 36-38, 46, 49, 51, 52) . Within this amino-terminal segment, the amino acid sequences of gB-1 and gB-2 are highly diverged (51) . Little information is available regarding the locations and type specificities of gB epitopes recognized by human HSV antibodies (21, 33, 52) . If gB-2 epitopes that react with human HSV-2 antibodies in a virus type-specific manner exist and are distinguishable from gB-2 cross-reactive epitopes, then the type-specific epitopes could be useful in the serodiagnosis of HSV-2 infections.
In this study, we determined the locations of human antibody-reactive linear (continuous) epitopes within the gB-2 polypeptide. gB-2 gene segments were expressed as recombinant proteins in Escherichia coli, and the gB-2 recombinant proteins were used as antigen targets in Western immunoblot assays. The results of the gB-2 recombinant protein assays were compared with results using HSV-2-and HSV-1-infected cell lysates as antigen targets in Western blot assays. Our data indicate that an amino-proximal gB-2 segment between aa 18 and 75 reacts preferentially with HSV-2 antibodies, and a carboxy-terminal gB-2 segment between aa 819 and 904 reacts strongly with both HSV-2 and HSV-1 antibodies. The relative specificities and sensitivities of the recombinant gB-2 assays compared with the HSV-infected cell lysate Western blot assays have not been determined. If the gB-2 recombinant protein from aa 18 to 75 is shown to be a virus type-specific antigen, then it may serve to complement HSV gG-based serodiagnostic tests.
MATERIALS AND METHODS
Human subjects. Human serum samples were obtained from three sources. Serum samples were collected from participants in a phase II clinical trial evaluating the immunogenic properties of recombinant gB-2 and HSV-2 gD-2 vaccines. Samples were drawn from these subjects prior to the administration of the HSV-2 vaccines. Serum samples were tested initially for the presence of HSV-1 and HSV-2 antibodies in a Western blot assay using HSV-infected cell lysates as antigen targets (see below). On the basis of the interpretation of the HSV Western blot assays, phase II clinical trial subjects (n ϭ 39) were classified as having serum IgG antibodies to neither HSV-1 nor HSV-2 (HSV-1Ϫ/2Ϫ) (n ϭ 22) or as having serum IgG antibodies to HSV-1 and not to HSV-2 (HSV-1ϩ/2Ϫ) (n ϭ 17). Sixty-seven serum samples were obtained from human subjects who were screened for participation in a phase III clinical trial evaluating the efficacy of a recombinant gB-2 plus gD-2 vaccine. These included 9 HSV-1Ϫ/2Ϫ samples, 16 HSV-1ϩ/2Ϫ samples, 21 samples that contained HSV-2 and not HSV-1 antibodies (HSV-1Ϫ/2ϩ), and 21 samples that contained both HSV-1 and HSV-2 antibodies (HSV-1ϩ/2ϩ). Eighteen additional HSV-1Ϫ/2ϩ serum samples were provided by Rhoda Ashley, University of Washington, Seattle, Wash.
HSV type-specific Western blot assays. Serum HSV antibodies were detected initially by using HSV-1-and HSV-2-infected human embryonic fibroblast cell lysates as antigen targets in Western blot assays. The interpretation of antibody virus type specificities has been described previously and includes detection of reactivities to native gG-1 and gG-2 (1, 2, 5, 8) . The HSV Western blot assays were performed and interpreted by Rhoda Ashley, University of Washington, Seattle, Wash.
Expression plasmid constructs. gB-2 DNA-encoded polypeptides were expressed in E. coli HB101 by using the pATH plasmid vectors (Table 1) (34) . pATH1, pATH10, pATH11, pATH20, pATH21, pATH22, and pATH23 plasmid DNAs were obtained from the American Type Culture Collection (ATCC 37695 through 37703, respectively). pATH vectors contain 5Ј transcription control elements and a portion of the first structural gene (trpE) of the E. coli tryptophan synthetase operon. gB-2 DNA segments were inserted into pATH DNA at restriction enzyme sites within a polylinker segment located 3Ј to the trpE gene. gB-2 DNA-encoded polypeptides were expressed as fusion proteins linked to a 37,000-Da polypeptide encoded by trpE.
gB-2 DNA segments were derived from plasmid pHS218 (56) , which contains the entire gB-2 coding sequence of HSV-2 strain 333. pHS218 plasmid DNA and DNA nucleotide sequence information were obtained from Rae Lyn Burke, Chiron Corporation, Emeryville, Calif. In the following descriptions of gB-2 DNA recombinant constructs, gB-2 nucleotide coordinates are numbered by counting the first nucleotide position of the first methionine codon as nucleotide (nt) 1.
Three overlapping constructs were made that expressed the amino-proximal portion (pGB2-SS2), the middle portion (pGB2-AP2), and the carboxy-proximal portion (pGB2-SS1) of the gB-2 polypeptide (Table 1) . For pGB2-SS2, pHS218 DNA was digested with SacI and SacII and the gB-2 DNA segment from nt coordinates 50 to 686 was ligated to vector pBluescript II KSϩ DNA (SacI-SacII digest) (Stratagene, La Jolla, Calif.). The pBluescript-gB2 recombinant plasmid was digested with BamHI and SacI, and the gB-2 DNA-containing insert was ligated to pATH23 DNA (BamHI-SacI digest). For pGB2-AP2, pHS218 was digested with ApoI and PstI, and the gB-2 fragment from nt 458 to 1511 was ligated to pATH20 DNA (EcoRI-PstI digest). For pGB2-SS1, pHS218 was digested with SacI, and the gB-2 fragment from nt 687 to 2711 was ligated to pATH20 DNA (SacI digest).
Additional gB-2 expression plasmids were made in order to further define antibody-reactive regions. pGB2-HA1 was constructed by digesting pGB2-SS2 DNA with HindIII and ApoI, and the gB-2 fragment from nt 50 to 458 was ligated to pATH23 DNA (HindIII-EcoRI digest). pGB2-SP1 was generated by digesting pGB2-SS1 DNA with PstI, leaving the gB-2 fragment from nt 687 to 1511, and religating the plasmid DNA ends. pGB2-SXO was constructed by digesting pGB2-SS1 DNA with XhoI and BamHI, and leaving the gB-2 fragment from nt 687 to 1879; the ends of the plasmid DNA were made blunt by digesting with nuclease S1, and the blunted ends were religated. pGB2-SMB was generated by digesting pHS218 with SmaI and BamHI, and the gB-2 fragment from nt 2454 to 3164 was ligated to pATH10 DNA (SmaI-BamHI digest). Recombinant DNAs were sequenced across the pATH-HSV junctions to confirm that the gB-2 fragments were inserted in the correct reading frame orientations.
exoIII and nuclease S1 deletion constructs. gB-2 antibody-reactive regions were mapped by testing antibodies for reactivities with nested sets of serially deleted recombinant proteins (30-32, 58, 59) . The serially deleted recombinant proteins were expressed by nested sets of plasmids that contained unidirectional deletions in the gB-2 DNA inserts. Unidirectional DNA deletions were made by digesting linearized plasmids DNAs with exonuclease III (exoIII) and nuclease S1 according to the protocol of Henikoff (26) . pGB2-SS2 DNA was prepared for 3Ј-to-5Ј exoIII-nuclease S1 deletions by cleavage at StyI (nt 593) and SacI (nt 682) sites located within the gB-2 DNA insert. An additional GB2-SS2 deletion construct, pGB2SS2-CEx132, was generated by digesting pGB2-SS2 DNA with PpuMI (nt 132) and SacI (nt 682), blunting the DNA ends with nuclease S1, and religating the DNA ends. pGB2-SS1 DNA was prepared for 3Ј-to-5Ј exoIIInuclease S1 deletions by cleavage at NcoI and KpnI sites located within the pATH20 polylinker. For making 5Ј-to-3Ј unidirectional deletions in pGB2-SS1 DNA, the pGB2-SS1 3Ј-to-5Ј deletion construct pGB2SS1-CEx2568 (which lacks the SacI site present at nt 2711 in pGB2-SS1) was digested with BsiWI (nt 833) and SacI (nt 682) at sites located within the gB-2 insert.
Serially truncated plasmid DNAs were religated and were used to transform E. coli HB101. The deleted plasmids expressed a nested series of progressively truncated recombinant proteins. The recombinant proteins were subjected to sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis under protein denaturing conditions, transferred to nitrocellulose membranes, and reacted with human serum antibodies in Western blot assays. Nucleotide sequences of the pATH-HSV DNA junctions were determined for selected plasmids that defined the boundaries of immunoreactive regions ( Table 2) .
Synthesis of recombinant fusion proteins, SDS-polyacrylamide gel electrophoresis, and recombinant gB-2 Western blot assays. The expression of recombinant fusion proteins in E. coli, SDS-polyacrylamide gel electrophoresis, and Western blot assays were performed as described previously (29) . In assays to detect the presence of HSV gB-2 antibody reactivities, the bacterial fusion proteins were partially purified from E. coli proteins by preparing detergentinsoluble protein fractions (29) . In epitope-mapping studies, whole bacterial lysates were used as antigen targets. Human serum samples were incubated with Western blots at a 1:200 dilution for 16 h at 4ЊC. Antigen-antibody complexes were detected by incubating the blots with alkaline phosphatase-conjugated goat anti-human IgG antibodies (Southern Biotechnology Associates, Birmingham, Ala.) at a 1:1,000 dilution for 4 h at room temperature. Alkaline phosphatase activity was detected by incubating the blots for 10 min in alkaline buffer containing nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate.
RESULTS
Reactivities of HSV-2 and HSV-1 antibodies with gB-2 recombinant proteins. Human serum samples (n ϭ 64) were tested in Western blot assays for IgG antibody reactivities to amino-proximal (pGB2-SS2), middle (pGB2-AP2), and carboxy-proximal (pGB2-SS1) gB-2 segments; these segments included gB-2 aa 18 to 228, aa 154 to 503, and aa 228 to 903, respectively (Fig. 1) . Amino acid coordinates were numbered by counting the first gB-2-encoded methionine residue as aa 1 and the leucine residue immediately preceding the gB-2 stop codon as aa 904. gB-2 aa 1 to 22 is a signal sequence that is cleaved from the polypeptide during gB-2 protein maturation (56) . The samples were tested initially for the presence of HSV-1 and HSV-2 antibodies by using HSV-1-and HSV-2-infected cell lysates as antigen targets in Western blot assays (4, 5) . Serum samples were classified as containing HSV-1 and HSV-2 antibodies on the basis of characteristic immunoblot banding patterns, including virus type-specific reactivities to gG-1 and gG-2. Samples included 23 samples from HSV-1Ϫ/2Ϫ subjects, 23 samples from HSV-1ϩ/2Ϫ subjects, and 18 samples from HSV-1Ϫ/2ϩ subjects.
All (18 of 18) serum samples from HSV-1Ϫ/2ϩ subjects reacted strongly with the amino-proximal gB-2 segment (aa 18 to 228) and with the carboxy-proximal segment (aa 228 to 903); 8 of 18 HSV-1Ϫ/2ϩ subjects also reacted with the middle gB-2 segment (aa 154 to 503). None (0 of 23) of the HSV-1ϩ/2Ϫ subjects reacted with the amino-proximal gB-2 segment or with the middle gB-2 segment; all (23 of 23) of the HSV-1ϩ/2Ϫ subjects reacted with the carboxy-proximal segment (aa 228 to 903). No antibody reactivities to the pGB2-SS2, pGB2-AP2, or pGB2-SS1 proteins were detected in the serum samples from HSV-1Ϫ/2Ϫ subjects (n ϭ 23). These findings suggested that HSV-2 infections elicit different antibodies that react with the amino-proximal and carboxy-proximal segments of gB-2. The data suggested further that HSV-1 infections induce antibodies that cross-react within the carboxy-proximal segment of gB-2 but do not induce antibodies that cross-react with linear epitopes located within the amino-proximal segment of gB-2.
Sixty-seven serum samples were then tested for GB2-SS2 and GB2-SS1 reactivities. These samples were obtained from participants in a phase III clinical trial evaluating the efficacy of a recombinant gB-2/gD-2 vaccine candidate. All subjects either had recurrent genital herpes or were the monogamous sex partners of subjects with recurrent genital herpes. Serum samples included 9 HSV-1Ϫ/2Ϫ subjects, 16 HSV-1ϩ/2Ϫ subjects, and 42 HSV-2ϩ subjects; among the 42 HSV-2ϩ subjects, 21 samples contained HSV-2 antibodies only (HSV-1Ϫ/2ϩ), and 21 samples contained both HSV-1 and HSV-2 antibodies (HSV-1ϩ/2ϩ). No antibody reactivities were seen in the HSV-1Ϫ/2Ϫ subjects to any of the gB-2 recombinant proteins. Of the 16 HSV-1ϩ/2Ϫ subjects, 3 samples showed weak reactivity to the GB2-SS2 protein and reacted strongly with the GB2-SS1 protein. All serum samples from subjects with HSV-2 antibodies reacted strongly with both the GB2-SS2 and the GB2-SS1 proteins. The results for all serum samples tested are shown in Table 3 . 
Localization of the gB-2 antibody-reactive region recognized preferentially by HSV-2 antibodies.
The amino-proximal gB-2 segment contained within the GB2-SS2 protein recognized by HSV-2 antibodies was further defined by reacting HSV-2 antibody-containing serum samples with nested sets of serially deleted gB-2 recombinant proteins. The carboxy-terminal boundary of this region was defined by using a nested set of recombinant proteins that contained carboxy-to-amino-terminal deletions in the pGB-SS2 protein (Table 2) .
Thirty-five HSV-1Ϫ/2ϩ serum samples were tested. All 35 serum samples reacted with pGB2SS2-CEx227 protein (aa 18 to 75). Three of the 35 serum samples had either no reactivity (or greatly reduced reactivity) to the pGB2SS2-CEx210 protein (aa 18 to 70), whereas 32 of 35 serum samples retained reactivity. By the next smaller deletion, the pGB2SS2-CEx194 protein (aa 18 to 64), only two serum samples retained strong reactivity. No serum samples reacted strongly with the pGB2SS2-CEx161 protein (aa 18 to 53). Representative Western blot assays of the deletion series proteins are shown in Fig.  2 .
Therefore, the major amino-proximal linear epitope (or epitopes) recognized by HSV-2 human IgG antibodies lies within the gB-2 segment from aa 18 to 75 (Fig. 2) . There is 46% amino acid sequence homology between this region of gB-2 and the corresponding region of gB-1 (HSV-1 Patton strain) (13) .
In 12 of 35 HSV-1Ϫ/2ϩ samples, persistent but markedly diminished reactivity was observed in deletion constructs smaller than pGB2SS2-CEx194 (aa 18 to 64). These samples were tested with more extensively deleted constructs in order to further define this minor reactivity. In 12 of 12 samples, antibodies reacted with the pGB2SS2-CEx144 protein (aa 18 to 48) but did not react with the pGB2SS2-CEx132 (aa 18 to 44) protein and more extensively deleted proteins. Therefore, this minor amino-proximal gB-2 specificity recognized by HSV-2 antibodies is contained within the gB-2 segment from aa 18 to 48.
Localization of a carboxy-terminal gB-2 segment recognized by both HSV-2 and HSV-1 antibodies. The major carboxyterminal segment recognized by HSV-2 antibodies and by cross-reactive HSV-1 antibodies was further localized. Serum samples were tested for reactivity with a nested set of carboxyto-amino-terminal deletion constructs derived from the pGB2-SS1 (aa 228 to 903) protein. HSV-1ϩ/2Ϫ samples that reacted with the pGB2-SS1 protein did not react with the largest deletion construct pGB2SS1-CEx2568 (aa 228 to 856) and more extensively deleted constructs. This observation suggested that the cross-reactive epitope(s) recognized by HSV-1 antibodies lies close to the gB-2 carboxy terminus. The gB-2 carboxyterminal construct pGB2-SMB (aa 819 to 904) was tested for reactivity with HSV-1 and HSV-2 antibody-containing serum samples. All HSV-1 antibody-containing samples tested (23 of 23) and all HSV-2 antibody-containing samples tested (42 of 42) reacted strongly with this segment (Fig. 3) . These observations indicate that the major epitope(s) of pGB2-SS1 (aa 228 to 903) recognized by HSV-2 antibodies and by HSV-1 crossreactive antibodies is also contained within the gB-2 segment (aa 819 to 904) encoded by pGB2-SMB. This strongly antibody-reactive region between aa 819 and 904 is contained within the gB-2 cytoplasmic domain (56) .
Localization of a second gB-2 cross-reactive region recognized by some HSV-2 antibodies and by some HSV-1 antibodies. Testing of HSV-2 and HSV-1 antibody-containing samples with the pGB2-SS1 deletion constructs indicated the presence of a second antibody-reactive segment. This segment was mapped by using nested sets of carboxy-to-amino-terminal deletions and (A and B) Western blots generated with identical proteins that were reacted with serum samples from two different HSV-1Ϫ/2ϩ subjects. Lane V contains the protein expressed by the pATH expression vector. Lane SS2 contains the GB2-SS2 protein. The remaining lanes contain proteins with carboxy-to-amino-terminal deletions in the GB2-SS2 protein; the numbers above the lane refer to the amino acid coordinate of the carboxy-terminal gB-2 amino acid in that construct (see Table 2 ). For the construct in lane X, the coordinate of the carboxy terminus was not determined. The numbers to the left of the panels refer to the mobilities of protein molecular mass standards (in kilodaltons). The map at the bottom depicts the gB-2 amino acid sequence from aa 18 to 228. The arrows above the amino acid sequence mark the carboxy termini of the selected deleted GB2-SS2 proteins used in the Western blot assays, and the numbers below the amino acid sequence refer to the amino acid coordinates of the carboxy termini. The (ϩ) and (Ϫ) symbols indicate that the antibodies in panel B reacted with (ϩ) or did not react with (Ϫ) the GB2-SS2-deleted protein. a Results are given as total number of samples with detectable reactivity by Western blot divided by the total number of samples tested. The GB2-SS2 protein includes aa 18 to 228, GB2-AP2 includes aa 154 to 503, GB2-SS1 includes aa 228 to 903, and GB2-SMB includes aa 819 to 904. Region F refers to the region recognized by some HSV-2 antibodies as displayed in Fig. 4 ; region G refers to the region recognized by most HSV-2 antibodies and approximately 50% of HSV-1 antibodies as displayed in Fig. 4 .
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amino-to-carboxy-terminal deletions in gB-2 recombinant proteins (Table 2 ). This gB-2 segment was recognized by antibodies present in 33 of 39 HSV-2 antibody-containing serum samples and by antibodies present in 13 of 25 HSV-1 antibodycontaining serum samples. Representative results are shown in Fig. 3 . Both the HSV-2 and the HSV-1 antibodies reacted with a GB2-SXO (aa 228 to 626) protein and did not react with the pGB2SS1-CEx1820 (aa 228 to 606) protein and more extensively deleted proteins. These data indicated that the carboxyterminal boundary lies between aa 606 and 626. Both the HSV-2 and the HSV-1 antibodies reacted with the pGB2SS1-NEx1690 (aa 564 to 856) protein and did not react with the pGB2SS1-NEx1837 (aa 613 to 856) protein and more extensively deleted proteins. These data indicate that the aminoterminal boundary of the immunoreactive region was localized between aa 564 and 613. Therefore, a second cross-reactive gB-2 epitope recognized by most HSV-2 antibody-containing samples and by approximately half of the HSV-1 antibodycontaining samples was localized to the segment between aa 564 and 626 (Fig. 3) .
DISCUSSION
We identified an amino-terminal region of the HSV-2 gB-2 (aa 18 to 75) that contains a linear epitope, or epitopes, recognized by human HSV-2 IgG antibodies. The gB-2 segment from aa 18 to 75 reacted strongly with antibodies from all serum samples that contained HSV-2 antibodies (n ϭ 58). This gB-2 segment also reacted weakly with antibodies present in 3 of 33 HSV-1ϩ and HSV-2Ϫ samples. The serum samples were initially categorized as containing HSV-2 and HSV-1 antibodies on the basis of the results of an HSV lysate Western blot assay.
Our data suggest that the gB-2 segment from aa 18 to 75 contains an epitope (or epitopes) that reacts with HSV-2 antibodies in a virus type-specific manner. The discordant results obtained in three samples using the assay for gB-2 aa 18 to 75 compared with the HSV lysate Western blot assay suggest three possibilities. (i) The gB-2 segment from aa 18 to 75 cross-reacts with gB-1 antibodies induced in some individuals by HSV-1 infections. (ii) The assay for gB-2 aa 18 to 75 reacts with HSV-2 antibodies in a virus type-specific manner but gave false-positive results in these three HSV-1ϩ/2Ϫ serum samples. (iii) The assay for gB-2 aa 18 to 75 reacts with HSV-2 antibodies in a virus type-specific manner and is more sensitive in detecting HSV-2 antibodies than is the HSV-2 Western blot assay. Clinical and demographic data support the third possibility. Two of the three HSV-2Ϫ/1ϩ subjects who reacted with the gB-2 aa 18 to 75 protein were the regular sex partners of HSV-2-seropositive people with a history of recurrent genital herpes; one of these samples contained both IgG and IgM antibodies that reacted with the gB-2 segment from aa 18 to 75, suggesting that an acute infection was present at the time the sample was obtained. The third subject had a history of recurrent genital herpes but was classified as HSV-1ϩ/2Ϫ on the basis of the HSV lysate Western blot assay. In these three subjects, it is possible that HSV-2 antibodies were present that were detected by the assay for gB-2 aa 18 to 75 but were not detected by the HSV lysate Western blot assay.
The serodiagnosis of acute HSV-2 infections in patients who have been infected previously with HSV-1 has been problematic because of an anamnestic response to HSV-2 and HSV-1 type-common antigens (4, 42) . In this situation, detection of antibodies to HSV-2 type-specific antigens is obscured by the strong antibody responses to type-common antigens (1). Difficulties in detecting HSV-2 type-specific antibodies by using the HSV lysate Western blot assay in subjects previously infected with HSV-1 may have resulted in the misclassification of samples reactive to gB-2 aa 18 to 75 as HSV-1ϩ/2Ϫ. Therefore, the gB-2 segment from aa 18 to 75 may contain virus type-specific epitope(s) recognized by human HSV-2 antibodies. The homologous gB-1 amino-terminal segment contains virus type-specific linear epitopes recognized by mouse monoclonal antibodies; some of these monoclonal antibodies have virus-neutralizing activity (14, 18, 21, 35, 36, 51) . Algorithms that model protein antigenicity suggest that the aminoterminal segments of gB-2 and gB-1 are potentially the most antigenic regions of the proteins (7). The complete gB amino acid sequences are 86% homologous, but gB-2 and gB-1 amino acid homology is 46% within the amino-terminal (aa 18 to 75) segment. Therefore, it is plausible that this gB-2 segment is a type-specific antigen that is recognized by HSV-2 antibodies and not by HSV-1 antibodies.
The gB-2 carboxy-terminal segment between aa 819 and 904 contains a dominant epitope(s) that reacted strongly with all HSV-2 and all HSV-1 antibody-containing samples. This carboxy-terminal segment is contained entirely within the gB-2 Western blots generated with identical proteins. Panels A and B were reacted with an HSV-1ϩ/2Ϫ serum sample, and panels C and D were reacted with an HSV-1Ϫ/2ϩ serum sample. Panels A and C include the GB2-SS1 protein and a nested series of amino-to-carboxy-terminal deletions in the GB2-SS1 protein; the numbers above the lanes refer to the amino acid coordinate of the amino terminus of each construct. Panels B and D contain the GB2-SS1 protein, the GB2-SMB protein, and a nested series of carboxy-toamino-terminal deletions in the GB2-SS1 protein; the numbers above the lanes refer to the amino acid coordinate of the carboxy terminus of each construct. The numbers to the left of the panels refer to the mobilities of protein molecular mass standards (in kilodaltons). The map at the bottom represents the gB-2 segment from aa 400 to 903. The arrows above the bar mark the locations of the carboxy termini of carboxy-to-amino-terminal deletions and the arrows below the bar mark the amino termini of the amino-to-carboxy-terminal deletions. The (ϩ) and (Ϫ) symbols indicate that the antibodies reacted with (ϩ) or did not react with (Ϫ) the recombinant proteins. cytoplasmic domain. The strong reactivities of HSV-1 antibodies with this gB-2 segment account, at least in part, for the observation that HSV-1 antibodies cross-react with native gB-2.
A third immunoreactive region recognized by HSV-2 antibodies lies within the segment between aa 564 and 626, immediately amino proximal to the membrane-spanning domain (Fig. 4) . This segment reacted with antibodies from most (85%) HSV-2-seropositive subjects tested and cross-reacted with antibodies from some but not all (52%) HSV-1-seropositive subjects tested.
Our analysis of gB-2-reactive antibodies is restricted to the characterization of antibodies that recognize linear (or continuous) protein-binding sites. The recombinant gB-2 polypeptides were subjected to SDS-polyacrylamide gel electrophoresis under fully denaturing conditions before being transferred to nitrocellulose blots. Therefore, gB-2 antibodies that are dependent on native protein conformation for binding would not be detected. gB-2 regions that contain linear antibodybinding sites were defined by using nested sets of serially deleted recombinant proteins. The resolution of this method for localizing linear epitopes is dependent on the spacing of the serially deleted proteins. The deletion-mapping technique defines a segment of gB-2 that contains one or more linear antibody-binding sites but does not define the minimum epitope recognized by those antibodies. This strategy has been used extensively by our group to localize human antibodyreactive segments of the Four Corners hantavirus and human papillomavirus antigens (29) (30) (31) (32) 59 ).
In acute human HSV infections, glycoprotein antibody reactivities appear sequentially, beginning at approximately 4 days after infection. In HSV-2 infections, gB-2 and then gD-2 antibodies appear first (2) . Seroconversion to all antigenic determinants requires at least 21 days after infection in most cases and may be delayed by antiviral therapy (3). gG-2 antibodies are detected most often at least 10 days after primary infection (40) .
A gB-2 virus type-specific antibody test could complement gG-based assays. Because gB-2 antibodies generally appear in the serum before gG-2 antibodies, gB-2 virus type-specific antibody assays may provide earlier diagnosis of acute HSV-2 infections. Identification of a type-specific epitope within HSV-1 gB-1 would provide a similar capability for defining HSV-1 antibody responses. Because gG-1 antibody detection appears to be a relatively less sensitive indicator of HSV-1 infections, a gB-1 virus type-specific antibody assay could be a useful tool in the serodiagnosis of HSV-1 infections.
